Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > CYDY

<< Previous

Bullboard Posts

Next >>

Comment by Bucknelly21on Jan 07, 2022 12:32pm

130 Views

Post# 34293427

RE:RE:RE:RE:CYDY

weren't you the one who said Nash would have value after the protocols and fda accepted the phase 3?

jfm1330 wrote: The oddity is Cytodyn, not Thera. If Thera get excellent results in oncology and the SP barely moves, than I will blame the management for not being able to sell a real good story. At this point, oncology is hope of a good story based on educated guesses by us, but this is not a confirmed fact. Possibility of failure or mild results is there. And again, I looked at Sutro, and even with good efficacy data on humans, their valuation is not very high. So even with some proof of efficacy, the SP will not go crazy. It should rise, maybe double, but not more than that unless results would be really spectacular.

SPCEO1 wrote: Even with the inevitable happening to CYDY (and still in the process of happening - how much longer before their CEO flees the country I wonder), it still has a market cap of $463 million versus TH's $274 million. So, despite the insanity at CYDY, investors somehow value it more highly than TH. Life is weird - very, very weird!

jfm1330 wrote: 0.70$ today, less than a year ago it was at 7.15$. So much for "promotion" I guess...